Primary source: Dailymotion Video Player
The compassionate use framework for Methotrexate has been renewed, with updated protocols for patient monitoring and safety reporting obligations for a period of three years starting July 28, 2026.
Maintaining rigorous pharmacovigilance for off-label Methotrexate use is crucial to ensure patient safety and support ongoing evaluations of treatment risks and benefits.
Healthcare providers must ensure patient registrations and comply with adverse event reporting as per the renewed compassionate use framework, which includes the collection and analysis of safety data.
Regulatory Intelligence Lead
Review before 2026-07-21.
Continuation of the CPC framework; mandatory registration of patients and reporting of adverse events by prescribing clinicians.
MAHs and healthcare providers must maintain rigorous PV reporting for off-label use within this framework. This includes the collection and analysis of safety data to support periodic evaluations of the risk-benefit balance for these specific indications.
Healthcare providers must ensure patient registrations and comply with adverse event reporting as per the renewed compassionate use framework, which includes the collection and analysis of safety data.
The ANSM has renewed the compassionate use framework (CPC) for Methotrexate, effective July 22, 2026. This renewal requires mandatory patient registration and adverse event reporting by healthcare providers. The framework will be in place for three years, with a new therapeutic use and patient monitoring protocol replacing the previous one.
What changed: The compassionate use framework for Methotrexate has been renewed, with updated protocols for patient monitoring and safety reporting obligations for a period of three years starting July 28, 2026.
Why it matters: Maintaining rigorous pharmacovigilance for off-label Methotrexate use is crucial to ensure patient safety and support ongoing evaluations of treatment risks and benefits.
Practical implication: Healthcare providers must ensure patient registrations and comply with adverse event reporting as per the renewed compassionate use framework, which includes the collection and analysis of safety data.
Published from the Firecrawl policy change extraction pipeline.
Ensure that all labeling and safety information reflects the updated product name 'Prasugrel Viatris' instead of 'Prasugrel Mylan'.
The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.
Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.
